Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Equity Income (2019 - 2025)

Historic Equity Income for BridgeBio Pharma (BBIO) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.

  • BridgeBio Pharma's Equity Income fell 14126.16% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.3 million, marking a year-over-year decrease of 37124.52%. This contributed to the annual value of -$31.2 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that BridgeBio Pharma reported Equity Income of -$15.8 million as of Q3 2025, which was down 14126.16% from -$20.2 million recorded in Q2 2025.
  • BridgeBio Pharma's Equity Income's 5-year high stood at -$6.6 million during Q3 2024, with a 5-year trough of -$20.2 million in Q2 2025.